TriSalus Life Sciences, Inc. (TLSI), a small-cap oncology technology company that pairs its Pressure-Enabled Drug Delivery (PEDD) infusion systems with an investigational immunotherapeutic, has seen its shares trade far below the levels most Wall Street analysts still project. The question facing investors is whether the stock can climb from roughly $2.85 toward a $10 central price target — a move that would require the shares to more than triple.
The central $10 target reflects five current analyst price targets that can be attributed to identifiable firms. H.C. Wainwright reiterated a Buy with a $12 target in October 2026; Lake Street reiterated Buy at $8 and Maxim Group at $14 (raised from $10) in the summer of 2026; JonesTrading reiterated Buy at $11; and Canaccord Genuity's William Plovanic lowered his target to $4 from $7 in November 2026 while keeping a Buy rating after the company's third-quarter miss and guidance reset.
Together these five targets average $9.80, rounded to the $10 figure used here. The spread is unusually wide — from $4 to $14 — reflecting sharply different assumptions about how quickly the company's expanded commercial organization can drive adoption. Analysts are uniformly constructive on the rating but divided on magnitude, with the more cautious view tied to execution risk in the sales force and the more optimistic view tied to the new TriNav Advance device and reimbursement tailwinds. This calculated mean is not an official published consensus and should be read as a range of opinion, not a guarantee.
Following the November 2026 earnings report, TLSI shares traded near $2.85, well below the 52-week high of $7.95 and near the lower end of a 52-week range of $2.20 to $7.95. Reaching $10 would require upside of roughly 251%, a very large move that would imply a full re-rating of the company from its recent micro-cap valuation.
TriSalus reported third-quarter 2026 revenue of about $12.9 million, up 11.3% year over year, with gross margin around 86%. Yet the company cut full-year 2026 revenue guidance to $46 million to $48 million from a prior $54 million to $57 million — its third reduction of the year. Management attributed the shortfall to slower-than-expected productivity among newly hired sales representatives and a faster shift toward "super-selective" Y90 procedures in small distal vessels that the legacy TriNav device could not address.
The most credible support comes from product and reimbursement catalysts rather than recent results. In September 2026 the FDA granted 510(k) clearance to TriNav Advance, which extends the PEDD platform to small distal vessels and could address the very procedural shift that hurt third-quarter growth. The company also highlights a roughly $2.5 billion U.S. addressable market across liver embolization and additional indications.
On the reimbursement side, the Centers for Medicare & Medicaid Services (CMS) finalized a calendar-year 2027 hospital outpatient payment increase for the C8004 mapping code to roughly $20,910 from about $11,874, effective January 1, 2027, alongside a new national office-based lab payment under G0577. Management points to these changes as a foundation for accelerated 2027 growth, and interim PROTECT trial data in thyroid artery embolization is expected in early 2027.
The principal obstacle is execution. Guidance has now been reset three times, and management has deferred full-year 2027 guidance, committing only to "meaningful double-digit growth" rather than the mid-30% pace previously implied. TriNav Advance is still in limited release and contributes nothing to the fourth quarter, so its commercial impact remains unproven.
The company is also unprofitable, with a trailing-twelve-month net loss and negative operating cash flow. Cash stood near $41 million as of September 30, 2026, and the share count has risen as a result of prior equity issuance, creating potential dilution risk. Slowing demand, further reimbursement or competitive setbacks, or a broader rotation away from speculative small-cap health care names could all keep the shares far from a double-digit target.
The shares trade well below both their 50-day and 200-day moving averages after the post-earnings decline, and the recent breakdown below roughly $3 leaves the 52-week low near $2.20 as a nearby support zone to monitor. On the upside, the prior $4 area and the 52-week high near $7.95 represent meaningful resistance levels; a sustained move toward $10 would require clearing both before any test of the central target becomes relevant.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. Key items to watch include the fourth-quarter 2026 results and any formal 2027 guidance, the broader commercial launch of TriNav Advance, the interim PROTECT data expected in early 2027, and the January 2027 implementation of the new CMS reimbursement rates. Analyst target revisions — such as the recent Canaccord cut — are also worth tracking, as they signal changing views on the pace of the commercial ramp.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name like TriSalus Life Sciences, such tools can help traders discover opportunities, keep an eye on positions, and spot shifting trends more efficiently than manual screening alone.
The $10 central target is derived from five analyst targets averaging $9.80, with a wide $4 to $14 range and uniform Buy ratings. Against a price near $2.85, reaching that level would require roughly 251% appreciation — a very large move that depends less on valuation than on a successful commercial re-acceleration. The FDA clearance of TriNav Advance and the 2027 CMS reimbursement increases offer genuine catalysts, but three consecutive guidance cuts, an unproven product launch, and persistent cash burn are substantial obstacles. Investors should watch 2027 guidance, TriNav Advance adoption, and clinical data before drawing conclusions, and no analyst target should be treated as a forecast of what the stock will actually do.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TLSI has been loosely correlated with PHG. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TLSI jumps, then PHG could also see price increases.
| Ticker / NAME | Correlation To TLSI | 1D Price Change % | ||
|---|---|---|---|---|
| TLSI | 100% | -19.30% | ||
| PHG - TLSI | 35% Loosely correlated | -0.69% | ||
| DXCM - TLSI | 31% Poorly correlated | +0.53% | ||
| TNDM - TLSI | 31% Poorly correlated | +0.32% | ||
| PRCT - TLSI | 28% Poorly correlated | +1.26% | ||
| CTKB - TLSI | 27% Poorly correlated | -0.52% | ||
More | ||||
| Ticker / NAME | Correlation To TLSI | 1D Price Change % |
|---|---|---|
| TLSI | 100% | -19.30% |
| Medical/Nursing Services industry (138 stocks) | 1% Poorly correlated | +1.72% |
| Health Services industry (239 stocks) | 1% Poorly correlated | -1.27% |